Effect of quetiapine on inflammation and immunity: a systematic review

References

• Ahern, G. P. (2011). 5-HT and the immune system. Current Opinion in Pharmacology, 11(1), 29–33. doi:10.1016/j.coph.2011.02.004
   PubMed Web of Science ®Google Scholar
• Al-Amin, M. M., Nasir Uddin, M. M., & Mahmud Reza, H. (2013). Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clinical Psychopharmacology and Neuroscience, 11(3), 144–151. doi:10.9758/cpn.2013.11.3.144
   PubMed Web of Science ®Google Scholar
• Bahramabadi, R., Samadi, M., Vakilian, A., Jafari, E., Fathollahi, M. S., & Arababadi, M. K. (2017). Evaluation of the effects of anti-psychotic drugs on the expression of CD68 on the peripheral blood monocytes of Alzheimer patients with psychotic symptoms. Life Sciences, 179, 73–79. doi:10.1016/j.lfs.2017.04.024
   PubMed Web of Science ®Google Scholar
• Baumeister, D., Ciufolini, S., & Mondelli, V. (2016). Effects of psychotropic drugs on inflammation: Consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology, 233(9), 1575–1589. doi:10.1007/s00213-015-4044-5
   PubMed Web of Science ®Google Scholar
• Baumeister, D., Russell, A., Pariante, C. M., & Mondelli, V. (2014). Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Social Psychiatry and Psychiatric Epidemiology, 49(6), 841–849. doi:10.1007/s00127-014-0887-z
   PubMed Web of Science ®Google Scholar
• Bechter, K., Reiber, H., Herzog, S., Fuchs, D., Tumani, H., & Maxeiner, H. G. (2010). Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction. Journal of Psychiatric Research, 44(5), 321–330. doi:10.1016/j.jpsychires.2009.08.008
   PubMed Web of Science ®Google Scholar
• Benros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., & Mortensen, P. B. (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. The American Journal of Psychiatry, 168(12), 1303–1310. doi:10.1176/appi.ajp.2011.11030516
   PubMed Web of Science ®Google Scholar
• Berger, M., Gray, J. A., & Roth, B. L. (2009). The expanded biology of serotonin. Annual Review of Medicine, 60, 355–366. doi:10.1146/annurev.med.60.042307.110802
   PubMed Web of Science ®Google Scholar
• Bian, Q., Kato, T., Monji, A., Hashioka, S., Mizoguchi, Y., Horikawa, H., & Kanba, S. (2008). The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32(1), 42–48. doi:10.1016/j.pnpbp.2007.06.031
   PubMed Web of Science ®Google Scholar
• Bolla, E., Bortolaso, P., Ferrari, M., Poloni, N., Callegari, C., Marino, F., Lecchini, S., Vender, S., & Cosentino, M. (2011). Are CYP1A2 1F and 1C associated with cloazpine tolerability? A preliminary investigation. Psychiatry Research, 189(3), 483. doi:10.1016/j.psychres.2011.03.011
   PubMed Web of Science ®Google Scholar
• Bortolasci, C. C., Spolding, B., Callaly, E., Martin, S., Panizzutti, B., Kidnapillai, S., Connor, T., Hasebe, K., Mohebbi, M., Dean, O. M., McGee, S. L., Dodd, S., Gray, L., Berk, M., & Walder, K. (2018). Mechanisms underpinning the polypharmacy effects of medications in psychiatry. The International Journal of Neuropsychopharmacology, 21(6), 582–591. doi:10.1093/ijnp/pyy014
   PubMed Web of Science ®Google Scholar
• Brinholi, F. F., Farias, C. C., Bonifácio, K. L., Higachi, L., Casagrande, R., Moreira, E. G., & Barbosa, D. S. (2016). Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 81, 411–415. doi:10.1016/j.biopha.2016.02.047
   PubMed Web of Science ®Google Scholar
• Çakici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M., & Sommer, I. E. C. (2019). An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychological Medicine, 49(14), 2307–2319. doi:10.1017/S0033291719001995
   PubMed Web of Science ®Google Scholar
• Cammer, W., & Zhang, H. (1999). Maturation of oligodendrocytes is more sensitive to TNF alpha than is survival of precursors and immature oligodendrocytes. Journal of Neuroimmunology, 97(1–2), 37–42. doi:10.1016/s0165-5728(99)00045-4
   PubMed Web of Science ®Google Scholar
• Cao, W., & Zheng, H. (2018). Peripheral immune system in aging and Alzheimer’s disease. Molecular Neurodegeneration, 13(1), 51. doi:10.1186/s13024-018-0284-2 141
   PubMedGoogle Scholar
• Colibazzi, T., Wexler, B. E., Bansal, R., Hao, X., Liu, J., Sanchez-Peña, J., Corcoran, C., Lieberman, J. A., & Peterson, B. S. (2013). Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. PLoS One, 8(2), e55783. doi:10.1371/journal.pone.0055783
   PubMed Web of Science ®Google Scholar
• Cosentino, M., & Marino, F. (2013). Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: Teaching old drugs new tricks? Journal of Neuroimmune Pharmacology, 8(1), 163–179. doi:10.1007/s11481-012-9410-z
   PubMed Web of Science ®Google Scholar
• Cosentino, M., Zaffaroni, M., Legnaro, M., Bombelli, R., Schembri, L., Baroncini, D., Bianchi, A., Clerici, R., Guidotti, M., Banfi, P., Bono, G., & Marino, F. (2016). Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis. Journal of Neuroimmunology, 298, 82–89. doi:10.1016/j.jneuroim.2016.07.008
   PubMed Web of Science ®Google Scholar
• Cosentino, M., Zaffaroni, M., Trojano, M., Giorelli, M., Pica, C., Rasini, E., Bombelli, R., Ferrari, M., Ghezzi, A., Comi, G., Livrea, P., Lecchini, S., & Marino, F. (2012). Dopaminergic modulation of CD4 + CD25 (high) regulatory T lymphocytes in multiple sclerosis patients during interferon- b therapy. Neuroimmunomodulation, 19(5), 283–292. doi:10.1159/000336981
   PubMed Web of Science ®Google Scholar
• Cross, A. J., Widzowski, D., Maciag, C., Zacco, A., Hudzik, T., Liu, J., Nyberg, S., & Wood, M. W. (2016). Quetiapine and its metabolite norquetiapine: Translation from in vitro pharmacology to in vivo efficacy in rodent models. British Journal of Pharmacology, 173(1), 155–166. doi:10.1111/bph.13346
   PubMed Web of Science ®Google Scholar
• De Berardis, D., Campanella, D., Gambi, F., La Rovere, R., Carano, A., Conti, C. M., Sivestrini, C., Serroni, N., Piersanti, D., Di Giuseppe, B., Moschetta, F. S., Cotellessa, C., Fulcheri, M., Salerno, R. M., & Ferro, F. M. (2006). The role of C-reactive protein in mood disorders. International Journal of Immunopathology and Pharmacology, 19(4), 721–725. doi:10.1177/039463200601900402
   PubMed Web of Science ®Google Scholar
• De Berardis, D., Conti, C. M., Campanella, D., Carano, A., Scali, M., Valchera, A., Serroni, N., Pizzorno, A. M., D'Albenzio, A., Fulcheri, M., Gambi, F., La Rovere, R., Cotellessa, C., Salerno, R. M., & Ferro, F. M. (2008). Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. International Journal of Immunopathology and Pharmacology, 21(2), 319–324. doi:10.1177/039463200802100208
   PubMed Web of Science ®Google Scholar
• De Berardis, D., Fornaro, M., Orsolini, L., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Serroni, N., De Lauretis, I., Girinelli, G., Mazza, M., Valchera, A., Carano, A., Vellante, F., Matarazzo, I., Perna, G., Martinotti, G., & Di Giannantonio, M. (2017). Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: An exploratory study in "real-world," everyday clinical practice. CNS Spectrums, 22(4), 342–347. doi:10.1017/S1092852916000572
   PubMed Web of Science ®Google Scholar
• Dell'Osso, B., Arici, C., Dobrea, C., Benatti, B., & Altamura, A. C. (2012). Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. International Clinical Psychopharmacology, 27(6), 310–313. doi:10.1097/YIC.0b013e328358f0c6
   PubMed Web of Science ®Google Scholar
• Demjaha, A., Lappin, J. M., Stahl, D., Patel, M. X., MacCabe, J. H., Howes, O. D., Heslin, M., Reininghaus, U. A., Donoghue, K., Lomas, B., Charalambides, M., Onyejiaka, A., Fearon, P., Jones, P., Doody, G., Morgan, C., Dazzan, P., & Murray, R. M. (2017). Antipsychotic treatment resistance in first-episode psychosis: Prevalence, subtypes and predictors. Psychological Medicine, 47(11), 1981–1989. doi:10.1017/S0033291717000435
   PubMed Web of Science ®Google Scholar
• El-Khalili, N. (2012). Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. Neuropsychiatric Disease and Treatment, 8, 523–536. doi:10.2147/NDT.S14369 Epub 2012 Nov 8.
   PubMed Web of Science ®Google Scholar
• Endres, D., Dersch, R., Hottenrott, T., Perlov, E., Maier, S., van Calker, D., Hochstuhl, B., Venhoff, N., Stich, O., & van Elst, L. T. (2016). Alterations in cerebrospinal fluid in patients with bipolar syndromes. Frontiers in Psychiatry, 7, 194. doi:10.3389/fpsyt.2016.00194
   PubMed Web of Science ®Google Scholar
• Feldhaus, B., Dietzel, I. D., Heumann, R., & Berger, R. (2004). Effects of interferon-gamma and tumor necrosis factor-alpha on survival and differentiation of oligodendrocyte progenitors. Journal of the Society for Gynecologic Investigation, 11(2), 89–96. doi:10.1016/j.jsgi.2003.08.004
   PubMedGoogle Scholar
• Feng, T., McEvoy, J. P., & Miller, B. J. (2020). Longitudinal study of inflammatory markers and psychopathology in schizophrenia. Schizophrenia Research, 224, 58–66. doi:10.1016/j.schres.2020.10.003
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea, E., Vértes, P. E., Flint, S. M., Turner, L., Mustafa, S., Hatton, A., Smith, K. G., Lyons, P. A., & Bullmore, E. T. (2016). Peripheral immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. Boussiotis VA, ed. PLoS One, 11(5), e0155631. doi:10.1371/journal.pone.0155631
   PubMed Web of Science ®Google Scholar
• Ferrari, M., Bolla, E., Bortolaso, P., Callegari, C., Poloni, N., Lecchini, S., Vender, S., Marino, F., & Cosentino, M. (2012). Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Research, 200(2–3), 1014–1017. doi:10.1016/j.psychres.2012.07.002
   PubMed Web of Science ®Google Scholar
• Ferrari, M., Godio, M., Callegari, C., Cosentino, M., & Marino, M. (2022). 6 Weeks monotherapy with antipsychotic drug reduced inflammatory markers in bipolar disorder patients. Psychopharmacology Bulletin, 52(2), 34–44.
   PubMedGoogle Scholar
• Fond, G., Resseguier, N., Schürhoff, F., Godin, O., Andrianarisoa, M., Brunel, L., Bulzacka, E., Aouizerate, B., Berna, F., Capdevielle, D., Chereau, I., D’Amato, T., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Lançon, C., Llorca, P. M., Mallet, J., … Leboyer, M, the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. (2018). Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: Results from the national FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience, 268(6), 541–553. doi:10.1007/s00406-017-0847-1
   PubMed Web of Science ®Google Scholar
• Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry, 21(12), 1696–1709. doi:10.1038/mp.2016.3
   PubMed Web of Science ®Google Scholar
• Goldstein, B. I., Kemp, D. E., Soczynska, J. K., & McIntyre, R. S. (2009). Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. The Journal of Clinical Psychiatry, 70(8), 1078–1090. doi:10.4088/JCP.08r04505
   PubMed Web of Science ®Google Scholar
• Guo, Y. F., Fu, H. B., Liu, Z. Y., Lu, W., Luo, K. Y., Zhu, H. R., Ning, W. D., Chen, F., Yang, L. Y., & Zhou, X. D. (2017). Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia. Experimental and Therapeutic Medicine, 13(3), 873–876. doi:10.3892/etm.2017.4075
   PubMed Web of Science ®Google Scholar
• Haring, L., Koido, K., Vasar, V., Leping, V., Zilmer, K., Zilmer, M., & Vasar, E. (2015). Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index. Schizophrenia Research, 169(1–3), 22–29. doi:10.1016/j.schres.2015.08.027
   PubMed Web of Science ®Google Scholar
• Hefner, G., Shams, M. E., Unterecker, S., Falter, T., & Hiemke, C. (2016). Inflammation and psychotropic drugs: The relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology ( Psychopharmacology), 233(9), 1695–1705. doi:10.1007/s00213-015-3976-0
   PubMed Web of Science ®Google Scholar
• Himmerich, H., Schönherr, J., Fulda, S., Sheldrick, A. J., Bauer, K., & Sack, U. (2011). Impact of antipsychotics on cytokine production in-vitro. Journal of Psychiatric Research, 45(10), 1358–1365. doi:10.1016/j.jpsychires.2011.04.009
   PubMed Web of Science ®Google Scholar
• Hodo, T. W., de Aquino, M. T. P., Shimamoto, A., & Shanker, A. (2020). Critical neurotransmitters in the neuroimmune network. Frontiers in Immunology, 11, 1869. doi:10.3389/fimmu.2020.01869
   PubMed Web of Science ®Google Scholar
• Igue, R., Potvin, S., Bah, R., Stip, E., Bouchard, R. H., Lipp, O., Gendron, A., & Kouassi, E. (2011). Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(7), 1695–1698. doi:10.1016/j.pnpbp.2011.05.011
   PubMed Web of Science ®Google Scholar
• Jaehne, E. J., Corrigan, F., Toben, C., Jawahar, M. C., & Baune, B. T. (2015). The effect of the antipsychotic drug quetiapine and its metabolite norquetiapine on acute inflammation, memory and anhedonia. Pharmacology, Biochemistry, and Behavior, 135, 136–144. doi:10.1016/j.pbb.2015.05.021
   PubMed Web of Science ®Google Scholar
• Jensen, N. H., Rodriguiz, R. M., Caron, M. G., Wetsel, W. C., Rothman, R. B., & Roth, B. L. (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 33(10), 2303–2312. doi:10.1038/sj.npp.1301646
   PubMed Web of Science ®Google Scholar
• Kao, Y. C., Ko, C. Y., Wang, S. C., & Liu, Y. P. (2016). Protective effects of quetiapine on metabolic and inflammatory abnormalities in schizophrenic patients during exacerbated stage. The Chinese Journal of Physiology, 59(2), 69–77. doi:10.4077/CJP.2016.BAE370
   PubMed Web of Science ®Google Scholar
• Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015). Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. The Lancet. Psychiatry, 2(3), 258–270. doi:10.1016/S2215-0366(14)00122-9
   PubMed Web of Science ®Google Scholar
• Kim, H., Bang, J., Chang, H. W., Kim, J. Y., Park, K. U., Kim, S. H., Lee, K. J., Cho, C. H., Hwang, I., Park, S. D., Ha, E., & Jung, S. W. (2012). Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. European Journal of Pharmacology, 678(1–3), 55–60. doi:10.1016/j.ejphar.2011.12.017
   PubMed Web of Science ®Google Scholar
• Ko, C. Y. 1., & Liu, Y. P. 2. (2016). Disruptions of sensorimotor gating, cytokines, glycemia, monoamines, and genes in both sexes of rats reared in social isolation can be ameliorated by oral chronic quetiapine administration. Brain, Behavior, and Immunity, 51, 119–130. doi:10.1016/j.bbi.2015.08.003
   PubMed Web of Science ®Google Scholar
• Krause, D., Weidinger, E., Dippel, C., Riedel, M., Schwarz, M. J., Müller, N., & Myint, A. M. (2013). Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia. Psychiatria Danubina, 25(4), 389–397.
   PubMed Web of Science ®Google Scholar
• Kustrimovic, N., Marino, F., & Cosentino, M. (2019). Peripheral immunity, immunoaging and neuroinflammation in Parkinson’s disease. Current Medicinal Chemistry, 26(20), 3719–3753. doi:10.2174/0929867325666181009161048
   PubMed Web of Science ®Google Scholar
• Kustrimovic, N., Rasini, E., Legnaro, M., Marino, F., & Cosentino, M. (2014). Expression of dopaminergic receptors on human CD4+ T lymphocytes: Flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease. Journal of Neuroimmune Pharmacology, 9(3), 302–312. doi:10.1007/s11481-014-9541-5
   PubMed Web of Science ®Google Scholar
• Lanquillon, S., Krieg, J. C., Bening-Abu-Shach, U., & Vedder, H. (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 22(4), 370–379. doi:10.1016/S0893-133X(99)00134-7
   PubMed Web of Science ®Google Scholar
• León-Ponte, M., Ahern, G. P., & O'Connell, P. J. (2007). Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood, 109(8), 3139–3146. doi:10.1182/blood-2006-10-052787
   PubMed Web of Science ®Google Scholar
• Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet, 373(9657), 31–41. doi:10.1016/S0140-6736(08)61764-X
   PubMed Web of Science ®Google Scholar
• Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia [published correction appears in Am J Psychiatry 2020; 177(3):272]. The American Journal of Psychiatry, 177(4), 342–353. doi:10.1176/appi.ajp.2019.19010034
   PubMed Web of Science ®Google Scholar
• Levine, S. Z., Rabinowitz, J., Faries, D., Lawson, A. H., & Ascher-Svanum, H. (2012). Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research, 137(1–3), 141–146. doi:10.1016/j.schres.2012.01.014
   PubMed Web of Science ®Google Scholar
• Levite, M. (2016). Dopamine and T cells: Dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases disorders. Acta Physiologica (Oxford, England), 216(1), 42–89. doi:10.1111/apha.12476
   PubMed Web of Science ®Google Scholar
• Li, H., Hong, W., Zhang, C., Wu, Z., Wang, Z., Yuan, C., Li, Z., Huang, J., Lin, Z., & Fang, Y. (2015). IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. Journal of Affective Disorders, 174, 361–366. doi:10.1016/j.jad.2014.12.033
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209–1223. doi:10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Lopresti, A. L., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014). A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 48, 102–111. doi:10.1016/j.pnpbp.2013.09.017
   PubMed Web of Science ®Google Scholar
• Maan, J. S., Ershadi, M., Khan, I., & Saadabadi, A. (2021). Quetiapine. In StatPearls [Internet]. StatPearls Publishing.
   Google Scholar
• Mantere, O., Trontti, K., García-González, J., Balcells, I., Saarnio, S., Mäntylä, T., Lindgren, M., Kieseppä, T., Raij, T., Honkanen, J. K., Vaarala, O., Hovatta, I., & Suvisaari, J. (2019). Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis. Journal of Psychiatric Research, 109, 18–26. doi:10.1016/j.jpsychires.2018.11.008
   PubMed Web of Science ®Google Scholar
• Mei, F., Guo, S., He, Y., Wang, L., Wang, H., Niu, J., Kong, J., Li, X., Wu, Y., & Xiao, L. (2012). Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation. PLoS One, 7(8), e42746. doi:10.1371/journal.pone.0042746
   PubMed Web of Science ®Google Scholar
• Meyer, J. M., McEvoy, J. P., Davis, V. G., Goff, D. C., Nasrallah, H. A., Davis, S. M., Hsiao, J. K., Swartz, M. S., Stroup, T. S., & Lieberman, J. A. (2009). Inflammatory markers in schizophrenia: Comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry, 66(11), 1013–1022. doi:10.1016/j.biopsych.2009.06.005
   PubMed Web of Science ®Google Scholar
• Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry, 70(7), 663–671. doi:10.1016/j.biopsych.2011.04.013
   PubMed Web of Science ®Google Scholar
• Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 17(12), 1206–1227. doi:10.1038/mp.2012.47
   PubMed Web of Science ®Google Scholar
• Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N. (2019). Cytokine alterations in schizophrenia: An updated review. Frontiers in Psychiatry, 10, 892. doi:10.3389/fpsyt.2019.00892
   PubMed Web of Science ®Google Scholar
• Mössner, R., & Lesch, K. P. (1998). Role of serotonin in the immune system and in neuroimmune interactions. Brain, Behavior, and Immunity, 12(4), 249–271. doi:10.1006/brbi.1998.0532
   PubMed Web of Science ®Google Scholar
• Muller, N. (2018). Inflammation in Schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophrenia Bulletin, 44, 973–982. doi:10.1093/schbul/sby024
   PubMed Web of Science ®Google Scholar
• Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. (2015). Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience, 18(2), 199–209. doi:10.1038/nn.3922
   PubMed Web of Science ®Google Scholar
• Orlovska-Waast, S., Köhler-Forsberg, O., Brix, S. W., Nordentoft, M., Kondziella, D., Krogh, J., & Benros, M. E. (2019). Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: A systematic review and meta-analysis. Molecular Psychiatry, 24(6), 869–887. doi:10.1038/s41380-018-0220-4
   PubMed Web of Science ®Google Scholar
• Orsolini, L., Sarchione, F., Vellante, F., Fornaro, M., Matarazzo, I., Martinotti, G., Valchera, A., Di Nicola, M., Carano, A., Di Giannantonio, M., Perna, G., Olivieri, L., & De Berardis, D. (2018). Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Current Neuropharmacology, 16(5), 583–606. doi:10.2174/1570159X16666180119144538
   PubMed Web of Science ®Google Scholar
• Pan, Y. J., Wang, W. H., Huang, T. Y., Weng, W. H., Fang, C. K., Chen, Y. C., & Hwang, J. J. (2018). Quetiapine ameliorates collagen-induced arthritis in mice via the suppression of the AKT and ERK signaling pathways. Inflammation Research: Official Journal of the European Histamine Research Society, 67(10), 847–861. doi:10.1007/s00011-018-1176-1
   PubMed Web of Science ®Google Scholar
• Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppä, T., Härkänen, T., Koskinen, S., & Lönnqvist, J. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry, 64(1), 19–28. doi:10.1001/archpsyc.64.1.19
   PubMed Web of Science ®Google Scholar
• Pinoli, M., Marino, F., & Cosentino, M. (2017). Dopaminergic regulation of innate immunity: A review. Journal of Neuroimmune Pharmacology : The Official Journal of the Society on NeuroImmune Pharmacology, 12(4), 602–623. doi:10.1007/s11481-017-9749-2
   PubMed Web of Science ®Google Scholar
• Pollak, T. A., Lennox, B. R., Müller, S., Benros, M. E., Prüss, H., Tebartz van Elst, L., Klein, H., Steiner, J., Frodl, T., Bogerts, B., Tian, L., Groc, L., Hasan, A., Baune, B. T., Endres, D., Haroon, E., Yolken, R., Benedetti, F., Halaris, A., … Bechter, K. (2020). Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. The Lancet Psychiatry, 7(1), 93–108. doi:10.1016/S2215-0366(19)30290-1
   PubMed Web of Science ®Google Scholar
• Remington, G., Foussias, G., & Agid, O. (2010). Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs, 24(1), 9–20. doi:10.2165/11530250-000000000-00000
   PubMed Web of Science ®Google Scholar
• Réus, G. Z., Matias, B. I., Maciel, A. L., Abelaira, H. M., Ignácio, Z. M., de Moura, A. B., Matos, D., Danielski, L. G., Petronilho, F., Carvalho, A. F., & Quevedo, J. (2017). Mechanism of synergistic action on behavior, oxidative stress and inflammation following co-treatment with ketamine and different antidepressant classes. Pharmacological Reports, 69(5), 1094–1102. doi:10.1016/j.pharep.2017.04.021
   PubMed Web of Science ®Google Scholar
• Rubin, L. A., & Nelson, D. L. (1990). The soluble interleukin-2 receptor: Biology, function, and clinical application. Annals of Internal Medicine, 113(8), 619–627. doi:10.7326/0003-4819-113-8-619
   PubMed Web of Science ®Google Scholar
• Rybakowski, J. K. (2012). Bipolarity and inadequate response to antidepressant drugs: Clinical and psychopharmacological perspective. Journal of Affective Disorders, 136(1–2), e13–e19. doi:10.1016/j.jad.2011.05.005
   PubMed Web of Science ®Google Scholar
• Sacramento, P. M., Monteiro, C., Dias, A. S. O., Kasahara, T. M., Ferreira, T. B., Hygino, J., Wing, A. C., Andrade, R. M., Rueda, F., Sales, M. C., Vasconcelos, C. C., & Bento, C. A. M. (2018). Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4(+) T-cell subsets in multiple sclerosis patients. European Journal of Immunology, 48(8), 1376–1388. doi:10.1002/eji.201847525
   PubMed Web of Science ®Google Scholar
• Salagre, E., Dodd, S., Aedo, A., Rosa, A., Amoretti, S., Pinzon, J., Reinares, M., Berk, M., Kapczinski, F. P., Vieta, E., & Grande, I. (2018). Toward precision psychiatry in bipolar disorder: Staging 2.0. Frontiers in Psychiatry, 9, 641. doi:10.3389/fpsyt.2018.00641
   PubMed Web of Science ®Google Scholar
• Saller, C. F., & Salama, A. I. (1993). Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology, 112(2–3), 285–292. doi:10.1007/BF02244923
   PubMed Web of Science ®Google Scholar
• Sarkar, C., Chakroborty, D., & Basu, S. (2013). Neurotransmitters as regulators of tumor angiogenesis and immunity: The role of catecholamines. Journal of Neuroimmune Pharmacology : The Official Journal of the Society on NeuroImmune Pharmacology, 8(1), 7–14. doi:10.1007/s11481-012-9395-7
   PubMed Web of Science ®Google Scholar
• Sárvári, A. K., Veréb, Z., Uray, I. P., Fésüs, L., & Balajthy, Z. (2014). Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. Biochemical and Biophysical Research Communications, 450(4), 1383–1389. doi:10.1016/j.bbrc.2014.07.005
   PubMed Web of Science ®Google Scholar
• Scanzano, A., & Cosentino, M. (2015). Adrenergic regulation of innate immunity: A review. Frontiers in Pharmacology, 6, 171. doi:10.3389/fphar.2015.00171
   PubMed Web of Science ®Google Scholar
• Schmidt, A. J., Krieg, J. C., Clement, H. W., Hemmeter, U. M., Schulz, E., Vedder, H., & Heiser, P. (2010). Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro. Journal of Psychopharmacology (Oxford, England), 24(3), 349–354. doi:10.1177/0269881108096506
   PubMed Web of Science ®Google Scholar
• Shao, Y., Peng, H., Huang, Q., Kong, J., & Xu, H. (2015). Quetiapine mitigates the neuroinflammation and oligodendrocyte loss in the brain of C57BL/6 mouse following cuprizone exposure for one week. European Journal of Pharmacology, 765, 249–257. doi:10.1016/j.ejphar.2015.08.046
   PubMed Web of Science ®Google Scholar
• Shayegan, D. K., & Stahl, S. M. (2004). Atypical antipsychotics: Matching receptor profile to individual patient's clinical profile. CNS Spectrums, 9(10 Suppl 11), 6–14. doi:10.1017/s1092852900025086
   PubMed Web of Science ®Google Scholar
• Shen, H., Wu, D., Wang, S., Zhao, M., Sun, W., Zhu, X., Zhang, N., Yao, H., Cui, Q., & Xiao, H. (2018). Atypical antipsychotic administration in schizophrenic patients leads to elevated lipoprotein-associated phospholipase A2 levels and increased cardiovascular risk: A retrospective cohort study. Basic & Clinical Pharmacology & Toxicology, 123(6), 756–765. doi:10.1111/bcpt.13079
   PubMed Web of Science ®Google Scholar
• Słuzewska, A., Rybakowski, J. K., Laciak, M., Mackiewicz, A., Sobieska, M., & Wiktorowicz, K. (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences, 762, 474–476. doi:10.1111/j.1749-6632.1995.tb32372.x
   PubMed Web of Science ®Google Scholar
• Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., Mortensen, P. B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., … Collier, D. A, Genetic Risk and Outcome in Psychosis (GROUP). (2009). Common variants conferring risk of schizophrenia. Nature, 460(7256), 744–747. doi:10.1038/nature08186
   PubMed Web of Science ®Google Scholar
• Stromnes, I. M., & Goverman, J. M. (2006). Active induction of experimental allergic encephalomyelitis. Nature Protocols, 1(4), 1810–1819. doi:10.1038/nprot.2006.285
   PubMed Web of Science ®Google Scholar
• Sugino, H., Futamura, T., Mitsumoto, Y., Maeda, K., & Marunaka, Y. (2009). Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33(2), 303–307. doi:10.1016/j.pnpbp.2008.12.006
   PubMed Web of Science ®Google Scholar
• Sullivan, P. F., Fan, C., & Perou, C. M. (2006). Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International Society of Psychiatric Genetics, 141B(3), 261–268. doi:10.1002/ajmg.b.30272
   PubMed Web of Science ®Google Scholar
• Tamminga, C. A., & Medoff, D. R. (2000). The biology of schizophrenia. Dialogues in Clinical Neuroscience, 2(4), 339–348. doi:10.31887/DCNS.2000.2.4/ctamminga
   PubMedGoogle Scholar
• Tomasetti, C., Iasevoli, F., Buonaguro, E. F., De Berardis, D., Fornaro, M., Fiengo, A. L., Martinotti, G., Orsolini, L., Valchera, A., Di Giannantonio, M., & de Bartolomeis, A. (2017). Treating the synapse in major psychiatric disorders: The role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions. International Journal of Molecular Sciences, 18(1), 135. doi:10.3390/ijms18010135
   PubMed Web of Science ®Google Scholar
• Turra, B. O., Barbisan, F., Azzolin, V. F., Teixeira, C. F., Flores, T., Braun, L. E., de Oliveira Nerys, D. A., Rissi, V. B., de Oliveira Alves, A., Assmann, C. E., da Cruz Jung, I. E., Marques, L. P. S., & da Cruz, I. B. M. (2020). Unmetabolized quetiapine exerts an in vitro effect on innate immune cells by modulating inflammatory response and neutrophil extracellular trap formation. Biomedicine & Pharmacotherapy, 131, 110497. doi:10.1016/j.biopha.2020.110497
   PubMed Web of Science ®Google Scholar
• Ventriglio, A., Bellomo, A., Donato, F., Iris, B., Giovanna, V., Dario, D. S., Edwige, C., Pettorruso, M., Perna, G., Valchera, A., & De Berardis, D. (2021). Oxidative stress in the early stage of psychosis. Current Topics in Medicinal Chemistry, 21(16), 1457–1470. doi:10.2174/1568026621666210701105839
   PubMed Web of Science ®Google Scholar
• Wang, A. K., & Miller, B. J. (2018). Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression. Schizophrenia Bulletin, 44(1), 75–83. doi:10.1093/schbul/sbx035
   PubMed Web of Science ®Google Scholar
• Wang, L., Wang, R., Liu, L., Qiao, D., Baldwin, D. S., & Hou, R. (2019). Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 79, 24–38. doi:10.1016/j.bbi.2019.02.021
   PubMed Web of Science ®Google Scholar
• Zhu, S., Shi, R., Li, V., Wang, J., Zhang, R., Tempier, A., He, J., Kong, J., Wang, J. F., & Li, X. M. (2015). Quetiapine attenuates glial activation and proinflammatory cytokines in APP/PS1 transgenic mice via inhibition of nuclear factor-κB pathway. International Journal of Neuropsychopharmacology, 18(3), pyu022–pyu022. doi:10.1093/ijnp/pyu022
   Web of Science ®Google Scholar